In patients with type 2 diabetes at high cardiovascular (CV) risk, oral semaglutide demonstrated non-inferior cardiovascular safety to placebo, showing no significant increase in major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© 2024-2026 Hormone Insight. All rights reserved.